To date, the relative increase in granulocyte colony-stimulating factor (G-CSF) use in the study compared to clinical practice may be related both to the use that was permitted in the trial and to the greater attention of the researchers to the control of neutropenia that usually occurs in a clinical study. The gene discussed is CSF3; the disease is Decreased total neutrophil count.